Product news from the 09/05/06 News Brief

Share this article:
The FDA granted tentative approval to Mylan Pharmaceuticals’ Abbreviated New Drug Application for Fluoxetine capsules, a generic version of Eli Lilly’s Sarafem and Pulvules capsules, which had annual US sales of approximately $52 million for the 12 months ending June 30, 2006. Fluoxetine Capsules are indicated for the treatment of premenstrual dysphoric disorder (PMDD). They are the AB-rated
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.